APP and amyloidosis: Furthermore, recently, it has been reported that oral supplementation with B. breve MCC1274 for four months mitigated AD-like pathologies in AppNL-G-F mice overexpressing humanized Aβ with APP mutations (Swedish (NL), Beyreuther/Iberian (F), and Arctic (G)) without overexpressing APP [26], as indicated by a reduction in amyloidosis, attenuation of microglial activation, and improvement of synaptic plasticity in the hippocampus, which ultimately prevented memory impairment [27].